A Feasibility Study of the Surpass Aneurysm-Embolization System in Intracranial Arteries.

1. Subject understands the nature of the procedure and provides written informed consent;

2. Subject is willing to return to the investigational site for the thirty day and six month follow-up evaluations;

3. Age 18 years to 80 years;

4. Subject with a non-ruptured saccular or fusiform intracranial aneurysm arising from a parent vessel with a diameter of > 2mm and < 6mm;

5. Subject with an aneurysm that cannot be treated or is difficult to be treated with current available surgical or endovascular techniques.

1. Pregnancy and lactating women;

2. Participation in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study;

3. Allergy or contraindication to aspirin, clopidogrel, heparin, local or general anesthesia;

4. History of life threatening allergy to contrast dye;

5. Major surgery within previous 30 days or planned in the next 90 days after enrollment date;

6. Dementia or psychiatric problem that prevents the patient from completing required follow up;

7. Co-morbid conditions that may limit survival to less than one year;

8. Subject with anatomy not appropriate for endovascular treatement due to severe intracranial vessel tortuosity or stenosis, or intracranial vasospasm not responsive to medical therapy;

9. Subject with an intracranial mass (tumor (except meningioma), abscess, or other infection), or is undergoing radiation therapy for carcinoma or sarcoma of the head or neck region;

10. Subject has a history of bleeding diathesis or coagulopathy, international normalized ratio (INR) greater than 1.5, or will refuse blood transfusions;

11. Subject has a serum creatinine level greater than 2.0 mg/dL (within 7 days of procedure) which the investigator determines restricts the use of contrast agents;

12. Subject has a previously implanted intracranial stent associated with the symptomatic distribution within the past 12 weeks prior to enrollment date;

13. Stenting, angioplasty, or endarterectomy of an extracranial (carotid or vertebral artery) or intracranial artery within 30 days prior to enrollment date;

14. Subject has a previously implanted carotid stent associated with the symptomatic distribution within the past 12 weeks prior to enrollment date;

15. Subject has uncontrolled atrial fibrillation or known cardiac disorders likely to be associated with cardioembolic symptoms;

16. Subject had a subarachnoid hemorrhage within 12 weeks prior to the enrollment date;

17. Subject with resistance to ASA and/or Clopidogrel;

18. Subject with two or more aneurysms in associated distribution - unless the device is used to treat both aneurysms;

19. Subject has a non-treated arteriovenous malformation (AVM) in the territory of the target aneurysm;

20. Target aneurysm is expected to require more than one device.